Xylocaine + Epinephrine, multi dose vial 2%, 20 mL, 25 count box, Rx only, MFG: Fresenius Kabi USA LLC, NDC 63323-483-27
Published June 15, 2022 · Recall initiated: April 13, 2022
Summary
FDA records drug Class II recall D-1053-2022, published June 15, 2022 and initiated April 13, 2022. Recalling firm: Mckesson Medical-Surgical Inc. Corporate Office; Status: Terminated; Reported quantity: 33 trays/25 vials per tray; Lot: McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that impacted product may have been shipped to the customer. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
cGMP deviations: Temperature abuse
What to do
Voluntary: Firm initiated · Letter
Get an email if XYLOCAINE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- XYLOCAINE
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Distributor
- USA nationwide.
- UPC
- 0363323484576
- Lot
- McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that impacted product may have been shipped to the customer.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAXylocaine (lidocaine HCl Injection, USP), 1%, 200 mg per 20 mL (10 mg per mL), 25 Multiple-Dose Vials, 20 mL,July 29, 2026
- FDAXylocaine (lidocaine HCl Injection, USP), 1%, 500 mg per 50 mL (10 mg per mL), 25 Multiple-Dose Vials, 50 mL,July 29, 2026
- FDA2% Xylocaine DENTAL with Epinephrine 1:100,000 (Lidocaine HCI and Epinephrine Injection USP), packaged in aDecember 24, 2025
- FDAXylocaine + Epinephrine, multi dose vial 1%, packaged in a) 20 mL, 25-count box (NDC 63323-482-27) b) 50 mL,June 15, 2022
- FDADoxycycline Hyclate Tablets, USP, 100 mg, 50-count carton (10 tablets each blister pack x 5), Rx only, MFG:June 15, 2022
- FDAGlucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection, 1 mg per vial Diluent for Glucagon, 1mlJune 15, 2022
Questions about this recall
Was Xylocaine + Epinephrine, multi dose vial 2%, 20 mL, 25 count box, Rx only, MFG: Fresenius Kabi USA LLC, NDC 63323-483-27 recalled?
Yes. FDA published recall D-1053-2022 on June 15, 2022. Reported hazard: cGMP deviations: Temperature abuse
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: XYLOCAINE. UPC: 0363323484576.